Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Robert Armstrong, VP, Global External R&D at Eli Lilly is entrusted with perhaps the most challenging task in his organization - cherry-picking the best research partners to help enrich Lilly's pipeline of future drugs - yet keep costs on those multiple research projects as low as possible. Armstrong, who has struck many deals with Indian firms including a joint venture with Jubilant, advocates openness in communication with his partners, but said in an interview with PharmAsia News' India bureau that overcoming challenges and reaching targeted milestones is the true test for strong partnerships.
Advertisement

Related Content

Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
As Deals Shrink, Indian Companies Ask MNCs To Stay Open For Drug Discovery Partnerships - PharmAsia Summit
Excited By Unique Capabilities Of Zydus Cadila, Eli Lilly Partners For Research In Cardiovascular Drugs
Excited By Unique Capabilities Of Zydus Cadila, Eli Lilly Partners For Research In Cardiovascular Drugs
Advertisement
UsernamePublicRestriction

Register

SC076339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel